Skip to content

Based on the theory of 'liver and kidney homology' to explore the clinical application of TCM prevention and treatment in PATIENTS with HR-positive breast cancer

Based on the theory of 'liver and kidney homology' to explore the clinical application of TCM prevention and treatment in PATIENTS with HR-positive breast cancer

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200005735
Enrollment
Unknown
Registered
2022-03-17
Start date
2022-03-22
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

Experimental group:Oral Ruaishuhou prescription and Yishentiaogan prescription
Control group:Oral Add and subtract Ruaishuhou prescription

Sponsors

Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged between 18 and 65; 2. Patients diagnosed as breast cancer by pathology and HR positive by immunohistochemistry; 3. Completed surgery, chemotherapy, radiotherapy, and/or targeted therapy; 4. Have received AIs (anastrozole, Letrozole, exemestane) for at least 2 months; 5. TCM syndrome differentiation belongs to liver and kidney deficiency (symptoms include tenderness of waist and knee, stiffness of joints, dizziness, etc.); 6.KPS score =60; 7. The expected survival is more than 6 months; 8. Signed the informed consent and voluntarily accepted the treatment plan of the study.

Exclusion criteria

Exclusion criteria: 1. Bone mineral diseases: such as hypoparathyroidism or hyperthyroidism, malformed osteitis, osteogenesis imperfection, osteomalacia, etc.; 2. Diseases that affect bone metabolism, such as Cushing's syndrome, hyperthyroidism, rheumatism or rheumatoid arthritis; 3. Steroid hormones or anticonvulsants were used for more than 6 months before the study; 4. Used hormone replacement therapy within 6 months, such as glucocorticoid, parathyroid hormone, estrogen, etc.; 5. Had surgery related to extremities within 6 months; 6. Complicated with serious primary diseases of cardiovascular, liver, kidney and hematopoietic systems; 7. Patients with obvious disease progression and distant metastasis during the study; 8. Psychopaths with cognitive impairment or mental abnormalities.

Design outcomes

Primary

MeasureTime frame
WOMAC;

Secondary

MeasureTime frame
Bone density test;TCM symptom and sign scoring;Growth hormone(GH);Bone metabolism indicators (25-Hydroxy-vitamin-D, ß-CTX, osteocalcin);

Countries

China

Contacts

Public ContactCHEN HONGFENG

Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

chhfluk@126.com+86 18917763058

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026